
    
      This is a dose-escalation study. Sequential cohorts of subjects will receive increasing doses
      of ASP2409 or matching placebo.

      Subjects in all cohorts will stay confined in the unit for 3 days. All subjects will have
      scheduled outpatient visits and be followed for a minimum of 90 days.
    
  